{"nctId":"NCT01425203","briefTitle":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","startDateStruct":{"date":"2011-11-23","type":"ACTUAL"},"conditions":["Chronic Hepatitis C Genotype 1"],"count":238,"armGroups":[{"label":"RGT BOC + PR","type":"EXPERIMENTAL","interventionNames":["Drug: Boceprevir","Biological: peginterferon alfa-2b","Drug: Ribavirin"]},{"label":"PBO + PR (Control)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Biological: peginterferon alfa-2b","Drug: Ribavirin"]},{"label":"Crossover Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Boceprevir","Biological: peginterferon alfa-2b","Drug: Ribavirin"]}],"interventions":[{"name":"Boceprevir","otherNames":["SCH 503034"]},{"name":"Placebo","otherNames":[]},{"name":"peginterferon alfa-2b","otherNames":["PegIntron"]},{"name":"Ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* body weight ≥40 kg and ≤125 kg\n* previously documented CHC genotype 1 infection;\n* must have a liver biopsy with histology consistent with CHC and no other etiology\n* if cirrhosis present, must have an ultrasound within 6 months of the screening visit (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC)\n* agree to use acceptable methods of contraception with partner\n* previously untreated with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV or failing prior treatment with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV\n\nExclusion criteria:\n\n* co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus (Hepatitis B surface antigen \\[HBsAg\\] positive).\n* required discontinuation of previous interferon or ribavirin regimen for an adverse event (possibly or probably related)\n* treatment with ribavirin within 90 days and any interferon-alpha, based on the amendment, should be within 1 month prior to screening\n* treatment with any investigational drug within 30 days of the screening visit in this trial\n* evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy\n* diabetic and/or hypertensive with clinically significant ocular examination findings\n* clinical diagnosis of substance abuse of specified drugs within specified timeframes\n* any known pre-existing medical condition that could interfere with the participant's participation in and completion of the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Sustained Virologic Response At Follow-up Week 24 (SVR24) Among Participants Who Received At Least One Dose of Any Trial Medication (Full Analysis Set Population)","description":"SVR24 was defined as an undetectable plasma Hepatitis C Virus-ribonucleic acid (HCV-RNA) level at Follow-up Week 24 (FW24). If a participant was missing FW24 data and had undetectable HCV-RNA at FW12, the participant was considered a sustained virologic responder.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null},{"groupId":"OG001","value":"46.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving SVR24 Among Participants Who Received At Least One Dose of Experimental Trial Drug (Modified Intent-To-Treat [mITT] Population)","description":"SVR24 was defined as an undetectable plasma HCV-RNA level at FW24. If a participant was missing FW24 data and had undetectable HCV-RNA at FW12, the participant was considered a sustained virologic responder.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":null},{"groupId":"OG001","value":"46.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Early Virologic Response (EVR) At Treatment Week (TW) 8","description":"EVR was defined as an undetectable HCV-RNA level at TW 8. This analysis was conducted when all participants had completed 8 weeks of the study or had discontinued prior to TW 8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.4","spread":null},{"groupId":"OG001","value":"42.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":159},"commonTop":["Neutropenia","Pyrexia","Anaemia","Leukopenia","Dysgeusia"]}}}